文献速递皮肤肿瘤皮肤感染

英格兰皮肤癌发病率的种族差异:2013-2020年全国回顾性人群研究

Ethnicity and the epidemiology of skin cancer incidence: a national retrospective population-based study in England, 2013-20.
PubMed 文献 · Br J Dermatol · 2026-01-01

该研究基于英格兰国家疾病登记服务(NDRS)2013-2020年数据,分析黑色素瘤、肢端雀斑样黑色素瘤(ALM)、基底细胞癌(BCC)、皮肤鳞状细胞癌(cSCC)、皮肤T细胞淋巴瘤和卡波西肉瘤(KS)按七类种族分组的发病率。结果显示白人组黑色素瘤、cSCC和BCC的EASR显著高于亚洲和黑人组,但ALM在黑人组最高且更少经紧急疑似癌症路径转诊、分期更晚;KS在Other和黑人组显著更高。研究强调需改善种族数据收集以解决医疗不平等。

要点

  • 白人组黑色素瘤EASR是亚洲组的33倍、黑人组的16倍。
  • ALM在黑人组发病率最高,且更少经紧急疑似癌症路径转诊、分期更晚。
  • KS在Other和黑人组EASR显著更高,需关注免疫抑制人群。

核心结论

  • 英格兰皮肤癌发病率存在显著种族差异,白人组黑色素瘤、cSCC和BCC发病率远高于亚洲和黑人组。
  • ALM在黑人组发病率最高,且更少经紧急疑似癌症路径转诊、分期更晚。
  • KS在Other和黑人组EASR显著更高。
  • 高质量种族数据的缺乏阻碍了对健康差异的理解,需改进数据收集和定期审计。

研究设计与样本

  • 基于英格兰国家疾病登记服务(NDRS)癌症登记数据的全国回顾性人群研究,纳入2013-2020年黑色素瘤、ALM、BCC、cSCC、皮肤T细胞淋巴瘤和KS病例。
  • 肿瘤记录与人口普查数据、国家统计局(ONS)死亡数据、多重剥夺指数和医院 Episode 统计等数据集链接。
  • 种族数据按ONS七类标准化分组:White、Asian、Chinese、Black、Mixed、Other和Unknown。
  • 使用2013年欧洲标准人口计算欧洲年龄标准化率(EASR),报告为每10万人年(PY)。

主要发现

  • 黑色素瘤EASR(95%CI)白人组为27.3(27.1-27.5),亚洲组0.82(0.67-0.99),黑人组1.67(1.37-2.01);白人组是亚洲组的33倍、黑人组的16倍。
  • cSCC EASR白人组61.8(61.5-62.0),亚洲组4.55(4.15-4.97),黑人组4.73(4.17-5.34);白人组是亚洲组的14倍、黑人组的13倍。
  • BCC EASR白人组154(153-154),亚洲组5.59(5.16-6.04),黑人组5.98(5.35-6.65);白人组是亚洲组的26倍、黑人组的27倍。
  • ALM的EASR在黑人组最高,且ALM较黑色素瘤总体更少经紧急疑似癌症路径转诊、更可能分期更晚。
  • KS的EASR在Other和黑人组显著更高;Unknown种族比例从BCC的19.2%到ALM的5.0%不等。

关键数值与推荐

  • 黑色素瘤EASR白人组27.3(27.1-27.5)/10万人年,亚洲组0.82(0.67-0.99),黑人组1.67(1.37-2.01)。
  • cSCC EASR白人组61.8(61.5-62.0),亚洲组4.55(4.15-4.97),黑人组4.73(4.17-5.34)。
  • BCC EASR白人组154(153-154),亚洲组5.59(5.16-6.04),黑人组5.98(5.35-6.65)。
  • Unknown种族比例BCC为19.2%,ALM为5.0%。

临床怎么用

  • 临床应警惕黑人等少数族裔的ALM风险,其更少经紧急疑似癌症路径转诊且分期更晚,需加强早期识别和转诊。
  • 对Other和黑人组需关注KS风险,尤其免疫抑制人群。
  • 应改进种族数据的常规收集和审计,以识别和解决医疗服务不足人群的需求。

局限性

  • 种族数据存在Unknown比例(BCC达19.2%),可能影响发病率估计的准确性。
  • 缺乏高质量已发表的种族数据限制了健康差异的全面理解。
  • 研究为回顾性登记数据分析,可能存在数据链接和分类偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Skin cancers primarily affect people of White ethnicity and with lighter skin tones, but people of other ethnicities may face diagnostic delays and experience higher mortality, reflecting existing inequities in healthcare. OBJECTIVES: To show incidence data from the National Disease Registration Service (NDRS) cancer registry in England for skin cancers, stratified by the seven broad ethnic groups. METHODS: We used data from the NDRS from 2013 to 2020 to analyse melanoma, acral lentiginous melanoma (ALM), basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), cutaneous T-cell lymphoma and Kaposi sarcoma (KS). Tumour records were linked to datasets including census population data, Office for National Statistics (ONS) mortality data, Index of Multiple Deprivation and Hospital Episode Statistics. Ethnicity data were grouped into seven standardized broad ONS categories: White, Asian, Chinese, Black, Mixed, Other and Unknown. European age-standardized rates (EASRs) were calculated using the 2013 European Standard Population and are reported per 100 000 person-years (PY). RESULTS: Ethnic diversity in England increased between the 2011 and 2021 censuses. Proportions of cases with 'Unknown' ethnicity with registry data ranged from 19.2% for BCC to 5.0% for ALM. The EASR (with 95% confidence interval) of melanoma was 33 times higher in the White group (27.3, 27.1-27.5) than in the Asian group (0.82, 0.67-0.99) and 16 times higher in the White than in the Black ethnic group (1.67, 1.37-2.01). Similarly, cSCC was 14 times more common in the White group (61.8, 61.5-62.0) than in the Asian group (4.55, 4.15-4.97) and 13 times more common in the White than in the Black ethnic group (4.73, 4.17-5.34). BCC was 26 times more common in the White group (154, 153-154) than in the Asian group (5.59, 5.16-6.04) and 27 times more common in the White than in the Black ethnic group (5.98, 5.35-6.65). However, the EASR for ALM was highest in the Black ethnic group. ALM was less likely to be referred along the Urgent Suspected Cancer pathway and was more likely to present at a later stage than melanoma overall. The EASR for KS was significantly higher in the Other and Black ethnic groups. CONCLUSIONS: A lack of high-quality published ethnicity data hampers our understanding of health disparities. These findings emphasize the need for better collection of ethnicity data and regular audits to better understand and address the needs of populations underserved by healthcare resources. Skin cancer rates are increasing worldwide. There is a lack of information showing how this affects people from different ethnic groups. This study involved dermatologists from across the UK. We obtained data from the English Cancer Registry for six different types of skin cancer. We used seven broad ethnic groups: White, Asian, Chinese, Black, Mixed, Other and Unknown. This corresponds to the classification by the UK Office for National Statistics. Ethnic diversity increased between the 2011 and 2021 censuses. Availability of ethnicity data varies. Rates of ‘Unknown’ were between 5% and 19%. Rates of some cancers are much higher in White populations than in Asian and Black groups. These include melanoma, cutaneous squamous cell carcinoma and basal cell carcinoma. Acral lentiginous melanoma is more common in Black populations. It is often not referred along the Urgent Suspected Cancer pathway. Thus, it presents at a more advanced stage. It is then harder to treat and has worse outcomes for patients. Kaposi sarcoma is more common in the Other and Black ethnic groups. It is also seen more often in people with reduced immunity. We highlight the need to improve the collection of data on ethnicity in skin cancer. These data are essential to understand unmet healthcare needs. Communities with little reporting of data and fewer healthcare resources will benefit. Such data will also help inform clinicians, patients and policymakers.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Ahmed S, van Bodegraven B, Proby C, et al. Ethnicity and the epidemiology of skin cancer incidence: a national retrospective population-based study in England, 2013-20. Br J Dermatol. 2026. PMID: 40926687. doi:10.1093/bjd/ljaf352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。